Portal hypertension (elevated portal pressure >12 mmHg) results from cirrhotic fibrosis increasing hepatic vascular resistance, leading to splanchnic vasodilation (from nitric oxide overproduction) that worsens portal congestion. Consequences include esophageal and gastric varices (from portal-systemic collateral formation), ascites (from portal hypertension, splanchnic vasodilation, and renal sodium retention), hepatic encephalopathy (from shunting of nitrogenous waste past the liver), and hepatorenal syndrome (from severe splanchnic vasodilation). Variceal bleeding is the most dramatic complication, with high mortality.
Understand the compensated versus decompensated cirrhosis distinction—portal hypertension is present in compensated cirrhosis but may not manifest clinically until decompensation (variceal bleeding, ascites, encephalopathy). Study the splanchnic circulation changes and how they perpetuate portal hypertension.
Portal hypertension is not synonymous with cirrhosis; non-cirrhotic portal hypertension occurs from portal vein thrombosis, Budd-Chiari syndrome, and other causes. Varices are not present in all cirrhotic patients; their development and rupture depend on variceal size and wall tension (Laplace's law). Portal hypertension does not directly cause ascites; it requires additional factors (renal dysfunction, splanchnic vasodilation).
From your study of cirrhosis, you know that fibrosis replaces functional hepatic parenchyma with scar tissue, disrupting the normal liver architecture. This structural distortion has a hydraulic consequence: blood flowing through the portal vein — carrying nutrients from the gut to the liver — encounters dramatically increased resistance as it tries to navigate through fibrotic sinusoids. Portal pressure, normally 5–10 mmHg, rises above 12 mmHg, at which point complications begin to emerge. Everything that follows from portal hypertension can be understood through two linked physiological responses: collateral vessel formation as the body tries to find alternative drainage routes, and splanchnic vasodilation as a maladaptive compensatory response that ultimately makes things worse.
Varices are the most acutely dangerous consequence. When blood cannot easily pass through the liver, it backs up and finds alternate paths to the systemic venous circulation — dilating small venous channels at the gastroesophageal junction, around the rectum (hemorrhoids), and at the umbilicus (caput medusae). Esophageal varices are fragile because the submucosa cannot provide much external support, and the wall tension required to rupture them follows Laplace's law: tension = pressure × radius. As varices enlarge, a smaller pressure rise is needed to exceed wall tension. Variceal hemorrhage is catastrophic — the mortality of an index bleed reaches 20–30% — and rebleeding risk is high without intervention. Beta-blockers reduce portal pressure prophylactically; acute bleeding requires band ligation or transjugular intrahepatic portosystemic shunt (TIPS) placement.
Ascites develops through a more complex pathway than simple portal pressure overflow. The key trigger is splanchnic vasodilation driven by nitric oxide overproduction in the gut vasculature — vessels sensing portal congestion release NO, which dilates the splanchnic bed and pools blood there. The effective circulating volume sensed by the kidneys falls, activating the renin-angiotensin-aldosterone system (RAAS) and antidiuretic hormone. Renal sodium and water retention ensues, expanding plasma volume — but this extra volume preferentially pools in the peritoneal cavity because of the combination of elevated portal hydrostatic pressure and reduced plasma oncotic pressure from low albumin (reflecting synthetic dysfunction). The resulting ascites creates abdominal discomfort, early satiety, and — critically — a reservoir for bacterial infection: spontaneous bacterial peritonitis (SBP) occurs when gut bacteria translocate across compromised intestinal mucosa into ascitic fluid, producing an infection that can trigger acute decompensation.
Hepatic encephalopathy and hepatorenal syndrome represent the most severe downstream effects. When portal blood bypasses the liver through collaterals (or a surgically placed TIPS), nitrogenous compounds — particularly ammonia from gut bacterial proteolysis — reach the systemic circulation and brain without being cleared. Ammonia disrupts astrocyte function and neurotransmitter balance, causing the spectrum from mild cognitive slowing (grade I) to coma (grade IV). Hepatorenal syndrome, the most feared renal complication, occurs when splanchnic vasodilation is so severe that the kidneys receive inadequate perfusion despite expanded total body volume — the kidneys functionally "see" themselves as hypovolemic even when the patient is fluid-overloaded. Unlike intrinsic renal disease, the kidneys in hepatorenal syndrome are structurally normal and will recover function in a transplanted patient. This illustrates the central irony of advanced portal hypertension: the complications are not simple mechanical consequences of high pressure but a cascade of systemic pathophysiology — hemodynamic, immunologic, and neurohumoral — that follows from the liver's loss of its central regulatory role.